Furthermore, Watanabe et al. reported results from a phase 2 study (NEJ043 study), where the median PFS, OS, and ORR were 7.4 months (95% CI: 5.7-8.2), 23.1 months (95% CI: 13.1 - not reached), and 55.9%, respectively, in NSCLC patients harboring sensitizing EGFR mutations [11]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.